134036-53-6

Usage

Uses

Used in Pharmaceutical Industry:
TYRPHOSTIN B7 is used as an antiproliferative agent for targeting diseases caused by the hyperactivity of protein tyrosine kinases (PTKs). It selectively inhibits PTKs of key growth factors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF), thereby disrupting the cell signaling pathways that contribute to uncontrolled cell proliferation and the development of certain diseases.
Used in Cancer Research:
In cancer research, TYRPHOSTIN B7 is utilized as a selective inhibitor of PDGF receptor kinase, with an IC50 value of 20 μM in human bone marrow fibroblasts. It also displays comparatively weak inhibition of the EGF receptor (IC50 = 820 μM), making it a valuable tool for studying the roles of these growth factors in cancer progression and for developing targeted therapies against specific types of cancer.
Used in Drug Development:
TYRPHOSTIN B7 serves as a lead compound in the development of novel therapeutics for diseases associated with the dysregulation of PTKs. Its selective inhibition of PTKs can be leveraged to design more potent and specific drugs that target these enzymes, potentially leading to more effective treatments with fewer side effects.
Used in Cell Signaling Studies:
As a selective inhibitor of PTKs, TYRPHOSTIN B7 is also employed in cell signaling research to investigate the roles of these enzymes in various cellular processes. By understanding how PTKs contribute to cell growth, differentiation, and survival, researchers can gain insights into the molecular mechanisms underlying various diseases and identify potential therapeutic targets.

in vitro

previous study found that ag-370 inhibited pdgf receptor autophosphorylation and the tyrosine phosphorylation of intracellular protein substrates that coprecipitated with the pdgf receptor in digitonin-permeabilized fibroblasts and in intact fibroblasts. when compared with ag18, a potent egf receptor blocker, ag370 was more efficient in inhibiting pdgf-induced proliferation of fibroblasts and phosphorylation of the intracellular protein substrates. under the conditions in which ag370 could inhibit pdgf-induced mitogenesis and phosphorylation, ag18 did not alter [125i]pdgf internalization and enhance [125i]pdgf binding. these findings suggested that ag370 might have a therapeutic potential for treatment of diseases involving abnormal cellular proliferation induced by pdgf [1].

IC 50

20 μm for pdgf receptor kinase in human bone marrow fibroblasts

references

[1] bryckaert, m. c.,eldor, a.,fontenay, m., et al. inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. experimental cell research 199, 255-261 (1992).